Publication | Open Access

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer

Prodige 59-Durigast TrialGastrointestinal OncologyMedicineAdvanced Gastric CancerGastroenterologyPathologyClinical TrialsCancer TreatmentOncologyRadiation OncologyCancer ResearchHealth Sciences